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Background: There is a need for agents that suppress inflammation and progression of chronic obstructive
pulmonary disease. p38 mitogen-activated protein kinase (p38 MAPK) has been associated with this disorder, and
several inhibitors of this cascade are in clinical trials for its treatment, but their efficacy and utility are unknown. This
study evaluated the relationship between p38 MAPK activation and susceptibility to cigarette smoke (CS)-induced
emphysema, and whether its inhibition ameliorated the lung inflammation and injury in murine models of cigarette
smoke exposure.
Methods: In acute and chronic CS exposure, the activation and expression of p38 MAPK in the lungs, as well as
lung inflammation and injury (proteinase production, apoptosis, and oxidative DNA damage), were compared
between two mouse strains: C57BL/6 (emphysema-susceptible) and NZW (emphysema-resistant). The selective p38
MAPK inhibitor SB203580 (45 mg/kg) was administrated intra-peritoneally to C57BL/6 mice, to examine whether it
ameliorated cigarette smoke-induced lung inflammation and injury.
Results: Acute CS-induced lung inflammation (neutrophil infiltration, mRNA expressions of TNF-α and MIP-2),
proteinase expression (MMP-12 mRNA), apoptosis, and oxidative DNA damage were significantly lower in NZW than
C57BL/6 mice. p38 MAPK was significantly activated and up-regulated by both acute and chronic CS exposure in
C57BL/6 but not NZW mice. mRNA expression of p38 MAPK was also upregulated in C57BL/6 by chronic CS exposure
and tended to be constitutively suppressed in NZW mice. SB203580 significantly attenuated lung inflammation
(neutrophil infiltration, mRNA expressions of TNF-α and MIP-2, protein levels of KC, MIP-1α, IL-1β, and IL-6),
proteinase expression (MMP-12 mRNA), oxidative DNA damage, and apoptosis caused by acute CS exposure.
Conclusions: Cigarette smoke activated p38 MAPK only in mice that were susceptible to cigarette smoke-induced
emphysema. Its selective inhibition ameliorated lung inflammation and injury in a murine model of cigarette smoke
exposure. p38 MAPK pathways are a possible molecular target for the treatment of chronic obstructive pulmonary
disease.
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Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death worldwide [1], and further
increases in its prevalence and mortality are predicted
[2]. COPD is characterized by airway obstruction and
progressive lung inflammation associated with the influx
of inflammatory cells [3]. The inflammation in the re-
spiratory tract appears to be an amplification of the nor-
mal response to chronic irritants such as cigarette
smoke (CS). The underlying mechanisms are not under-
stood, but might be genetically determined. Lung inflam-
mation is further amplified by oxidative stress and excess
proteinases in the lung. These mechanisms lead to charac-
teristic COPD pathological changes [4]. Although emphy-
sema can be developed without enhancing inflammation
in some animal models [5,6], the central pathogenesis
of human COPD is still believed to be chronic lung
inflammation.
There is limited evidence that regular treatment with
long-acting β2-agonists, inhaled corticosteroids, and
combinations of these will decrease the rate of decline of
lung function [7]. However, most studies have indicated
that existing medications for COPD do not modify the
long-term decline in lung function that is the hallmark
of this disease [8-11], and only decrease symptoms and/
or complications. Corticosteroids have widely been used
in an attempt to modulate the chronic inflammatory re-
sponse and eventually stop disease progression. However,
they are largely ineffective in attenuating inflammation in
COPD patients [12]. Corticosteroid resistance might in-
volve the impaired activity of the enzyme histone deacety-
lase, and is probably related to oxidative stress [13].
Several alternative anti-inflammatory approaches, such as
anti-tumor necrosis factor (TNF) and phosphodiesterase
(PDE)-4 inhibitors, are being investigated for COPD treat-
ment, but have been unsuccessful to date [14,15]. There is
a pressing need for more effective anti-inflammatory
drugs for the treatment of COPD.
Inflammatory signals are generally initiated by the acti-
vation of multiple cell-surface receptors, then a limited
number of kinase-signaling molecules, followed by nu-
merous effector molecules [16-18]. Novel therapeutics
might target the most common molecules associated
with COPD, such as kinases. Indeed, activation of p38
mitogen-activated protein kinase (MAPK) has been asso-
ciated with COPD in humans [19]. A p38 MAPK inhibitor
was also shown to inhibit CS-induced inflammation in a
murine model [20]. It remains unclear whether such anti-
inflammatory effects are sufficient for suppressing the
pathogenesis responsible for CS-induced lung inflamma-
tion, and subsequent emphysema development [21-23].
Here we used a murine model of CS exposure to
evaluate the significance of p38 MAPK activation in
COPD pathogenesis and its potential as a moleculartarget for therapeutics. We compared MAPK activation
by CS exposure between two murine strains with differ-
ent susceptibility to emphysema. We then explored the
effects of the specific p38 MAPK inhibitor SB203580 on
CS-induced oxidative DNA damage, apoptosis, excessive
protease production, and lung inflammation.
Methods
Animals
Male C57BL/6 (emphysema-susceptible) and NZW
(emphysema-resistant) mice (6–8 weeks old) were pur-
chased from Japan SLC (Shizuoka, Japan). The mice
were housed in a temperature-controlled conventional
room, and supplied with laboratory chow and water ad
libitum for at least 4 weeks before starting the smoke ex-
posure. The study protocol was approved by the Animal
Research Committee of Kyoto University, Japan.
CS exposure
According to our previous protocol [24], mice were ex-
posed to CS in acute and chronic studies. In both stud-
ies, CS was generated by burning filter-cut standard
cigarettes (Kentucky 2R4F reference cigarette, Cigarette
Laboratory at the Tobacco and Health Research Institute,
University of Kentucky, Lexington, KY) using a smoke
generator (SG-200, Shibata Scientific Technology Ltd.,
Tokyo, Japan). CS was diluted to 3% with air to reduce
toxicity. In the acute study, mice were exposed to main-
stream CS in a Plexiglas box for 1 h daily for 3 or 6 days
(40 cigarettes/day) (Figures 1A, 2A, 3A and 4A). In the
chronic study, mice were exposed to CS from 10 ciga-
rettes/day, 5 days a week for 24 weeks using a nose-
breathing apparatus (Figure 5A). Experiments were
performed safely, and no mice were killed through
smoke exposure. Blood carboxyhemoglobin (COHb)
levels were approximately 30% in the acute study and
approximately 15% in the chronic study immediately
after CS exposure. They were reduced to 0–1% after
24 h exposure, and there was no daily accumulation
through repeated CS exposure. The levels of total par-
ticle matter were 395.8 mg/m3 in the acute study and
445.3 mg/m3 in the chronic study.
At 24 h after the last CS exposure, mice were anesthe-
tized with 70 mg/kg pentobarbital by intra-peritoneal in-
jection, and subjected to bronchoalveolar lavage. They
were then killed by exsanguination and the lungs were
extracted with tracheal cannulation. The right lungs
were snap-frozen in liquid nitrogen. The left lungs were
fixed with 10% formalin at a constant pressure of 25 cm
H2O for histological examinations.
p38 MAPK inhibitor injection
The selective inhibitor of p38 MAPK SB203580 (45 mg/kg;
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Figure 1 (See legend on next page.)
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Figure 1 Acute cigarette smoke model. A. To investigate the relationship between p38 MAPK activation and lung inflammation and injury
after CS exposure, C57BL/6 and NZW mice were exposed to air (no-smoke group) or CS for 3 days (n = 6). B-E. Inflammatory cell counts in BALF. BALF
total cell (B), macrophage (C) and neutrophil counts (D) were significantly increased by CS exposure in C57BL/6 mice, but to a lesser degree or not at
all in NZW mice. BALF lymphocyte counts were significantly decreased by CS exposure in both strains (E). F.G. mRNA expression of inflammatory
mediators in the lungs. The expression of 18S rRNA was used as an internal control. mRNA expression levels of TNF-α, MIP-2, and MMP-12
were significantly up-regulated by CS exposure in C57BL/6 mice (F), but to a lesser degree or not at all in NZW mice (G). H. Histological lung
differences after CS exposure between C57BL/6 and NZW mice. Mouse lungs exposed to CS demonstrated cell death, seen as cytoplasmic
vacuolization (circle) and cytoplasmic blebbing (arrow) of the bronchial epithelium. Acute CS exposure induced these changes in C57BL/6
mice but to a lesser degree in NZW mice. I. J. Apoptosis in the lungs following CS exposure assessed by immunohistochemistry. There were
significantly fewer apoptotic cells in NZW mice, as represented by ssDNA (I) and cleaved caspase-3 (J)-positive cells, compared with C57BL/6
mice. K. Oxidative stress following CS exposure evaluated by increased 8-OHdG levels of lung DNA using an ELISA. CS exposure caused a
marked increase in 8-OHdG levels of mouse lungs in both strains, but to a lesser extent in NZW than in C57BL/6 mice. *p < 0.05 compared
with corresponding non-smoke groups. †p < 0.05 compared with C57BL/6 smoke groups. n = 6 for each experimental set.
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ate CS-induced lung inflammation and injury. Mice
were exposed to CS according to the acute study protocol
(40 cigarettes/day for 3 days), and were treated by intra-
peritoneal injection with SB203580 or vehicle (dimethyl-
sulfoxide) 30 min before every CS exposure (Figure 2A). A
separate experiment was performed to examine the thera-
peutic effect of SB203580 where mice were exposed to CS
for 6 days and treated with SB203580 on days 4 to 6
(Figure 3A).
Bronchoalveolar lavage (BAL) and the cell differential
Lungs were lavaged five times with 1 ml cold saline
through an intratracheal cannula. The lavage fluid was
collected and centrifuged to determine the inflammatory
cell differential (Shandon Scientific Ltd, Cheshire, UK).
At least 600 cells were counted on each cytospin slide
stained with Diff-Quik (Dade Behring, Switzerland)
under a light microscope.
RNA isolation and real-time Polymerase Chain Reaction
(PCR)
Total RNA was extracted from right lung tissue using TRI-
zol (Invitrogen, Carlsbad, CA), according to the manufac-
turer’s instructions. Single-stranded complementary DNA
(cDNA) was synthesized from 1 μg total RNA using the
SuperScript III Reverse Transcription Kit (Invitrogen).
cDNA was amplified and quantified using the Applied Bio-
systems 7300 Real-Time PCR System (Applied Biosystems,
Foster City, CA) with oligonucleotide PCR primer pairs
and fluorogenic probes (TaqMan Gene Expression Assay,
Applied Biosystems) for TNF-α, matrix metalloproteinase-
12 (MMP-12), chemokine (C–C motif) ligand 5 (RANTES),
macrophage-inflammatory protein-2 (MIP-2), interferon-γ
(IFN-γ) and p38 MAPK (Applied Biosystems catalogue
numbers Mm00443258_m1, Mm00500554_m1, Mm0130
2428_m1, Mm00436450_m1, Mm00801778_m1, and Mm
00442491_m1, respectively). 18 s ribosomal RNA (rRNA;
Applied Biosystems catalogue number 4310893E) was used
as an endogenous control.BioPlex cytokine array
In order to examine anti-inflammatory effects of the
MAPK inhibitor at a protein level, lung homogenates
of C57 mice (non-smoke, CS-exposed, CS-exposed and
SB-injected) were subjected to BioPlex cytokine assay
(Bio-Rad Laboratories, Richmond, CA). Twenty-three
chemokines and cytokines (IL-1α, IL-1β, IL-2, IL-3, IL-
4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13,
IL-17, Eotaxin, G-CSF, GM-CSF, IFN-γ, KC, MCP-1,
MIP-1α, MIP-1β, RANTES, TNF-α) were measured ac-
cording to the manufacturer’s instruction. Data were
normalized with protein concentration.
8-hydroxydeoxyguanosine (8-OHdG) Enzyme-Linked
Immunosorbent Assay (ELISA)
Total DNA was extracted from right-lung tissue using a
QIAamp DNA Mini Kit (Qiagen, Valencia, CA) accord-
ing to the manufacturer’s instructions. 8-OHdG levels in
the DNA samples were analyzed using an ELISA kit
(New 8-OHdG Check; Japan Institute for the Control of
Aging, Nikken SEIL, Shizuoka, Japan), according to the
manufacturer’s instructions. Briefly, 8-OHdG antibody
plus sample DNA were added to a 96-well plate precoated
with 8-OHdG and incubated overnight at 4°C. The plate
was then incubated with horseradish peroxidase-conjugated
secondary antibody for 1 h at room temperature followed
by 15 min substrate reaction with 3,3′, 5,5′-tetramethylben-
zidine. The reaction was terminated by the addition of
phosphoric acid, and absorbance was measured at 450 nm.
All assays were performed in duplicate and the average con-
centration of 8-OHdG, normalized per ng total DNA, was
calculated for each sample.
Western blotting for mitogen-activated protein kinases
(MAPKs)
To assess MAPK activation, different sets of mice re-
ceived a single exposure to the same 3% diluted CS, and
were then sacrificed as described above at 0 h, 0.25 h,
1 h, 3 h, 6 h, 12 h, and 24 h after the start of CS expos-
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Figure 2 (See legend on next page.)
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Figure 2 p38 MAPK activation. A. To assess MAPK activation, C57BL/6 and NZW mice were exposed to acute CS, and sacrificed at 0 h, 0.25 h,
1 h, 3 h, 6 h, 12 h, and 24 h from the start of CS exposure. B-E. Phosphorylated and total levels of p38 MAPK, ERK, and JNK in the lungs were
analyzed by western blotting, with β-actin as an indicator for equal protein loading. Phosphorylation of p38 MAPK in the lungs was confirmed in
C57BL/6 mice, but not in NZW mice. Phosphorylation of ERK and SAPK/JNK was noted in both strains in response to CS exposure. Western blots
are representative of three independent experiments evaluating murine lungs at 1 hr after the start of acute CS exposure (C, D, E). The intensities of
the electrophoretic bands were quantified and expressed as p-MAPK/t-MAPK. p-MAPK, phosphorylated-MAPK; t-MAPK, total MAPK. *p < 0.05 compared
with corresponding non-smoke groups. †p < 0.05 compared with C57BL/6 smoke groups. n = 3 for each experimental set. F-I. Phosphorylated and
total p38 MAPK following acute CS exposure were evaluated by immunohistochemistry. Acute CS exposure caused a marked increase in the number
of phosphorylated p38-positive cells in the alveolar walls of C57BL/6 mice, but not NZW mice (F). Total numbers of p38-positive cells were
not increased by acute CS exposure (G). Chronic CS exposure caused a marked increase in the numbers of both phosphorylated and total
p38-positive cells in the alveolar walls of C57BL/6 mice, but not NZW mice (H, I). p-p38, phosphorylated-p38; t-p38, total p38. *p < 0.05
compared with corresponding non-smoke groups. †p < 0.05 compared with C57BL/6 smoke groups. n = 6 for each experimental set.
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amide gel electrophoresis (SDS-PAGE) followed by western
blotting with primary antibodies for phosphorylated and
total p38 MAPK, phosphorylated and total extracellular
signal-regulated kinase (ERK), and phosphorylated and total
stress activated protein kinase (SAPK)/c-Jun N-terminal
kinase (JNK) (Cell Signaling, Beverly, CA, respectively).
Equal loading of the sample was determined by quantita-
tion of protein as well as by reprobing membranes for β-
actin (Imgenex, San Diego, CA) as a housekeeping protein.
The blots were visualized using enhanced chemilumines-
cence fluid (ECL plus, Amersham, Buckinghamshire, UK).
The intensities of electrophoretic bands were quantified
using Quantity One 1-D analysis software (Bio-Rad,
Hercules, CA) and expressed as the ratio to β-actin.
Immunohistochemistry
Apoptosis was assessed by immunohistochemistry accord-
ing to our previous reports [24]. Briefly, formalin-fixed lung
sections were incubated with a rabbit polyclonal anti-single
stranded DNA (ssDNA) primary antibody (1:100 dilution;
DakoCytomation California Inc., Carpinteria, CA) and a
rabbit polyclonal anti-cleaved caspase-3 primary antibody
(1:400 dilution; Cell Signaling, Danvers, MA). Staining was
performed using the DAKO EnVision + system (peroxid-
ase/3′-diaminobenzidine [DAB]; DAKO, Kyoto, Japan) and
counterstained with 1% methylgreen. Immunoreactive cells
were counted in at least five fields, and expressed as the
positive cell ratio to the length of the alveolar septa.
Immunohistochemistry of p38 MAPK was performed
using a rabbit monoclonal primary antibody against the
active form of p38 (phospho-p38) MAPK (dilution
1:100; Cell Signaling, Beverly, CA). Staining and count-
ing were performed using the same methods as the
apoptosis evaluation.
Evaluation of lung pathology and quantification of
emphysema
The left lungs were fixed with 10% formalin at a con-
stant pressure of 25 cm H2O, cut sagittally in 4-μm sec-
tions, and stained with hematoxylin and eosin (HE) forhistological analysis. Findings were quantified using a
four-point scoring system (0, normal; 3, severe) by two
analysts blinded to the groups according to a previous
method [25]. At least three sections were used for the
analysis of each mouse. Periodic acid-Schiff (PAS) stain
was performed to evaluate mucus production of airways.
For the evaluation of emphysematous change after
chronic CS exposure, we calculated the mean linear
intercept (Lm) and the destructive index (DI) according
to previous methods [24,26].
Statistical analysis
Results are expressed as means ± standard deviations
(SDs). Statistical analysis was performed using JMP soft-
ware version 6 (SAS institute Inc., Cary, NC). Groups
were compared by two-way analysis of variance (ANOVA)




Lung inflammation and injury were evaluated 24 h after
the last CS exposure (Figure 1A). The bronchoalveolar
lavage fluid (BALF) total cell and macrophage counts
were significantly increased by CS exposure in C57BL/6,
but not NZW, mice (Figure 1B, 1C). The BALF neutro-
phil counts were significantly increased in both strains,
but to a significantly lesser extent in NZW mice com-
pared with C57BL/6 mice (Figure 1D). Lymphocytes
were significantly decreased in response to CS in both
strains (Figure 1E).
Messenger RNA (mRNA) expression levels of the in-
flammatory cytokines TNF-α and MIP-2 were signifi-
cantly up-regulated by CS exposure in C57BL/6 mice
(1.8-fold and 14.0-fold, respectively), but to a signifi-
cantly lesser extent in NZW mice (0.88-fold and 2.7-
fold, respectively) (Figure 1F, 1G). There was no signifi-
cant up-regulation of RANTES or IFN-γ by CS exposure
in either strain. MMP-12 was also up-regulated by CS
exposure (4.3-fold), but to a significantly lesser extent in
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Figure 3 (See legend on next page.)
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Figure 3 Acute cigarette smoke model (prophylactic model). A. To explore the effects of a specific p38 MAPK inhibitor, C57BL/6 mice were
exposed to air or CS for 3 days, and were treated by intra-peritoneal injection with vehicle (dimethysulfoxide) or SB203580 (45 mg/kg) 30 min
before every CS exposure for 3 days as prophylaxis (n = 6). B-E. SB203580 significantly suppressed the increase in total cell counts and neutrophil
counts in BALF. F. SB203580 significantly suppressed the lung mRNA expression levels of TNF-α, MMP-12, and MIP-2. G. SB203580 significantly
suppressed the lung protein levels of KC, MIP-1α, IL-1β, and IL-6. H.I. SB203580 significantly suppressed the ssDNA-positive and cleaved caspase-3-
positive cells in the alveolar septa as assessed by immunohistochemistry. J. SB203580 significantly suppressed the lung 8-OHdG production as
assessed by an ELISA. *p < 0.05 compared with non-smoke group. †p < 0.05 compared with smoke group. n = 6 for each experimental set.
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vealed severe lung injury in the form of cytoplasmic
vacuolization and cytoplasmic blebbing of the bronchial
epithelium indicating necrotic cell death (Figure 1H). The
NZW mice showed significantly less severe cytoplasmic
vacuolization (0.99 ± 0.52 vs. 1.74 ± 0.45, respectively) and
blebbing (1.13 ± 0.46 vs. 2.61 ± 0.60, respectively) than
C57BL/6 mice, according to a semi-quantitative histo-
logical analysis. There was not mucus overproduction
evaluated by PAS stain in the acute CS exposure model
(Additional file 1: Figure S1C).
The apoptosis of lung cells was also enhanced by CS ex-
posure in both strains of mice, as represented by an in-
creased number of single-stranded DNA (ssDNA)-positive
or cleaved caspase-3-positive cells (Additional file 1: Figure
S1A, 1B). Apoptotic cells were mainly localized to the alveo-
lar septa. The NZW mice had significantly fewer ssDNA-
positive and cleaved caspase-3-positive cells compared with
the C57BL/6 mice after CS exposure (Figure 1I, 1 J).
Oxidative DNA damage in the lungs was markedly en-
hanced in the C57BL/6 mice by CS exposure, as repre-
sented by increased 8-OHdG levels in lung DNA
(Figure 1K). The oxidative DNA damage levels were sig-
nificantly lower in the NZW mice after CS exposure.
Chronic CS exposure
C57BL/6 and NZW mice were exposed to air (no-smoke
group) or for 24 weeks in the chronic study (n = 6)
(Figure 5A). Air-space dilatation and destruction wereacute CS model (therapeutic model) 
day 1 day 7day 4
Air/CS





C57BL/6 Vehicle and SB203580 (n=6)
BA
Figure 4 Acute cigarette smoke model (therapeutic model). A. As a th
days to fully develop lung inflammation and were subsequently treated by
(45 mg/kg) 30 min before CS exposure at days 4 to 6. B. Therapeutic admi
compared with non-smoke group. †p < 0.05 compared with smoke group.evaluated by Lm and DI respectively. Both were signifi-
cantly increased following CS exposure in C57BL/6 but
not NZW mice (Figure 5B, 5C, 5D). There was not
mucus overproduction evaluated by PAS stain in the
chronic CS exposure model (Additional file 1: Figure
S3C).
p38 MAPK activation
In preliminary acute CS time course experiment (n = 1),
the phosphorylation of p38 MAPK in the lungs was con-
firmed at 0.25 h, 1 h, 3 h, and 6 h after the start of CS
exposure in C57BL/6 mice, but was not seen in NZW
mice even at 24 h after exposure (Figure 2A, Additional
file 1: Figure S2A). Notably, the baseline levels (without
CS exposure) of total and phosphorylated p38 MAPK
were much lower in NZW mice than C57BL/6 mice. By
contrast, the phosphorylation of ERK and SAPK/JNK
was noted in both strains of mice in response to CS ex-
posure. Then, we performed three independent experi-
ments evaluating murine lungs at 1 hr after the start of
acute CS exposure. Western blots are representative of
three independent experiments (Figure 2B). The inten-
sities of the electrophoretic bands were quantified and
expressed as p-MAPK/t-MAPK (Figure 2C, 2D, 2E). p38
MAPK activation were not detected in chronic (24 wk)
models by Western blots (Additional file 1: Figure S1B).
Immunohistochemical analysis revealed that acute CS
exposure (3 d) markedly increased the number of
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Figure 5 Chronic cigarette smoke model. A. C57BL/6 and NZW mice were exposed to air (no-smoke group) or for 24 weeks in the chronic
study (n = 6). B. Black and white conversion of lung photomicrographs of non-smoke and smoke group mice at 24 weeks. C-D. Air-space dilatation
and destruction were evaluated by Lm and DI respectively. Both were significantly increased following CS exposure in C57BL/6 but not NZW mice.
*p < 0.05 compared with corresponding non-smoke groups. †p < 0.05 compared with C57BL/6 smoke groups. n = 6 for each experimental set.
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6 mice, but not in NZW mice (Figure 2F, Figure 2G,
Additional file 1: Figure S2C). In the chronic study, the
number of phospho-p38-positive cells was also signifi-
cantly increased in C57CL/6 mice (198% of control),
but not in NZW mice (113% of control) in the chronic
study (Figure 2H, 2I).
The mRNA levels of p38 MAPK were significantly up-
regulated by CS exposure in C57BL/6 mice in the chronic
study, but not in the acute study (Additional file 1:
Figure S2E, S2I). There was also no significant up-
regulation of p38 MAPK mRNA expression levels in
NZW mice, but they were significantly lower than those
in C57BL/6 mice after chronic CS exposure. The ex-
pression levels of MMK3, MMK6 and MAPKAPK-2
were not up-regulated in acute CS exposure (Additional
file 1: Figure S2F-H).
Acute CS model (prophylactic and therapeutic model)
Administration of the selective p38 MAPK inhibitor
SB203580 significantly suppressed the increase in total cell
counts and BALF neutrophils following 3 days of CS ex-
posure (by 52.1% and 73.6%, respectively) (Figure 3B, 3D).
Lung injury due to acute CS exposure was ameliorated by
injected SB203580: there was significantly less cytoplasmic
vacuolization (1.31 ± 0.21 vs. 1.82 ± 0.48, respectively) and
blebbing (1.76 ± 0.55 vs. 2.70 ± 0.84, respectively) in mice
injected with SB203580 compared with controls, as evalu-
ated by the histological lung injury score. SB203580significantly reduced the up-regulation of TNF-α, MIP-2,
and MMP-12 mRNA expression levels (by 60.1%, 62.6%,
and 71.9%, respectively) (Figure 3F). Protein levels of che-
mokines and pro-inflammatory cytokines such as KC,
MIP-1α, IL-1β, and IL-6 were elevated in the lungs of
C57BL/6 mice in response to CS exposure and SB203580
significantly suppressed the augmentation (by 36.7%,
42.8%, 14.1%, and 11.7%, respectively) (Figure 3G). The
other 19 cytokines examined including TNF-α were not af-
fected by CS exposure. SB203580 also significantly reduced
the increase in ssDNA-positive or cleaved caspase-3-
positive apoptotic cells (by 32.3% and 43.0%, respectively)
(Figure 3H, 3I). 8-OHdG production induced by acute CS
exposure was significantly attenuated by the administration
of SB203580 (by 64.0%) (Figure 3J).
In addition to prophylaxis, therapeutic effects of SB203580
were examined where SB203580 successfully attenuated
BALF inflammatory cells by 28.8% (Figure 4B).
Discussion
This study demonstrated that cigarette smoking acti-
vated p38 MAPK only in mice that were susceptible to
CS-induced emphysema, and that the selective inhibition
of p38 MAPK ameliorated lung injury and inflammation
in a murine model of CS exposure. Lung inflammation,
proteinase production, apoptosis, and oxidative stress
were markedly activated in susceptible C57BL/6 mice,
but less so in resistant NZW mice, and this was paral-
leled by the activation of p38 MAPK in both the acute
Marumo et al. BMC Pulmonary Medicine 2014, 14:79 Page 10 of 14
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between p38 MAPK activation and susceptibility to CS-
induced emphysema. Moreover, the selective p38 MAPK
inhibitor SB203580 significantly ameliorated lung in-
flammation, proteinase production, apoptosis, and oxi-
dative DNA damage in C57BL/6 mice. These results
might establish the basis for using p38 MAPK pathways
as novel molecular targets for the treatment of COPD.
The present study evaluated the significance of p38
MAPK activation in COPD pathogenesis and its poten-
tial as a molecular target in COPD therapeutics. In
recent years, steps have been taken to delineate the
intracellular signaling cascades that mediate inflamma-
tion, in order to clarify the pathogenesis of various in-
flammatory diseases and to develop novel therapeutics.
Much attention has been given to members of the
MAPK superfamily due to their consistent activation by
pro-inflammatory cytokines, and their role in nuclear
signaling. This superfamily includes ERKs (also known
as p42/p44), JNKs (also known as SAPKs) and p38
MAPK (also known as cytokine-suppressive binding pro-
tein or CSBP). ERKs are activated by growth factors and
mitogenic stimuli, whereas p38 and JNK are regulated
by stress-inducing signals (such as ultraviolet irradiation
and osmotic shock) and pro-inflammatory cytokines
[27]. Interest in the p38 family has been particularly in-
tense following the discovery that p38 MAPK inhibitors
have an anti-inflammatory effect in models of arthritis and
inflammatory angiogenesis in vivo, suppressing the ex-
pression of inflammatory cytokines, including interlekin-8
(IL-8), TNF-α, and MMPs [28-30].
An association between COPD and the MAPK path-
way was suggested by Yao et al., who reported that both
phosphorylated and total levels of p38 MAPK increased
in the lungs of C57BL/6 mice in response to acute CS
exposure [31]. Activation of this pathway was also de-
tected in human COPD by Renda et al. [19]; they ob-
served that active phosphorylated p38-positive alveolar
macrophages and alveolar wall cells were increased in
patients with severe and mild/moderate COPD, com-
pared with smoking and nonsmoking controls. Although
these studies suggest an association of p38 MAPK acti-
vation and COPD, the causal relationship between the
two remains unclear. One approach to understanding
this is to use an animal model to identify differences in
smoke-induced changes between individuals who do or
do not go on to develop emphysema. We therefore com-
pared emphysema-susceptible C57BL/6 and resistant
NZW mouse strains by subjecting them to short-term
CS exposure.
Major COPD pathogenesis, including lung inflamma-
tion, apoptosis, oxidative DNA damage, and proteinase
expression, was enhanced only in the susceptible strain
after 3 days of CS exposure (Figure 1). In addition,24 weeks of CS exposure caused emphysema only in the
same susceptible strain (Figure 5). These results suggest
that our animal model was suitable for emulating COPD.
p38 MAPK activation varied greatly between the two
strains soon after CS exposure, indicating that the inter-
strain difference was not a consequence, but rather a
cause, of the disease (Additional file 1: Figure S2A). This
was corroborated by the experiments using a p38 MAPK
inhibitor (Figures 3, 4). However, similar inter-strain dif-
ferences were not observed for ERK or JNK, suggesting
that the up-regulation of these cascades by CS exposure
might be independent of emphysema development. We
therefore speculate that p38 MAPK is critical for the ini-
tiation of the cascade of events leading to emphysema.
In the present study, the phosphorylation of p38
MAPK of the whole lung was detected at one hour from
the beginning of CS exposure, but it was not detected
after three days CS exposure in acute CS model, whereas
the phosphorylation in IHC was detected after three
days CS exposure in acute CS model. The discrepancy of
the phosphorylation of p38 MAPK between WB and
IHC was probably due to the cell source. Our IHC ana-
lysis revealed that p38 MAPK was activated in alveolar
wall cells. Therefore, p38 MAPK activation was diluted
in the whole lung analysis such as WB, resulting in that
p38 MAPK activation in WB was detected only in very
short time course with intense lung inflammation. CS-
induced p38 MAPK was also regulated at the mRNA
level. Significant differences were found in the expres-
sion of p38 MAPK mRNA between the two strains after
CS exposure after the development of emphysema (Add-
itional file 1: Figure S2I). Baseline p38 MAPK mRNA ex-
pression level evaluated by realtime PCR is higher in
C57BL/6 than NZW, which may reflect higher total p38
MAPK level evaluated by IHC in C57BL/6 than in
NZW. Acute CS exposure induced short time intense in-
flammation with significant phosphorylation of p38
MAPK in C57BL/6, but without up-regulation of p38
MAPK mRNA. Chronic CS exposure induced long term
mild inflammation with up-regulation of p38 MAPK
mRNA in C57BL/6. MAPKs are generally activated by
the phosphorylation of threonine and tyrosine residues
within a signature sequence T-X-Y (single letter code) by
a dual-specificity MAPK kinase (MEK or MKK) [32].
Therefore, this activation can be evaluated as phosphor-
ylated MAPK/total MAPK. Although transcriptional
regulation of p38 MAPK has not been reported, similar
regulation of the ERK signaling pathway (MEK2) was
previously observed [33]. Clarification of p38 MAPK
transcriptional regulation would allow an alternative ap-
proach to COPD therapeutics to be developed.
The differences in p38 MAPK expression between sus-
ceptible and resistant strains suggest that p38 MAPK ex-
pression might be useful as a biomarker of COPD, and
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the differences were observed regardless of smoke ex-
posure and before the development of emphysema. The
detection of p38 MAPK activation in humans could be
carried out non-invasively using material such as in-
duced sputum or peripheral whole blood, and could be
useful for predicting disease susceptibility. This potential
is currently under investigation in our department.
Moreover, once p38 MAPK inhibitors are established as
COPD therapeutics, the monitoring of p38 MAPK activ-
ity could also predict therapeutic responses and disease
management.
As MAPKs are involved in critical steps for many in-
flammatory signals, they are promising therapeutics for
a wide variety of inflammatory diseases. Medicherla
et al. reported the first anti-inflammatory effect of a p38
MAPK inhibitor in a murine model of CS exposure [20].
They found that the selective p38α inhibitor SD-282 suc-
cessfully ameliorated CS-induced lung inflammation
measured by the cell differential using bronchoalveolar
lavage, lung histology, and the pro-inflammatory cyto-
kines cyclooxygenase-2 (COX-2) and IL-6. However, it is
not clear whether the anti-inflammatory effect of p38
MAPK inhibitors is sufficient to prevent emphysema de-
velopment. In murine models of CS-induced emphy-
sema, it can take as long as 24 weeks to develop
emphysema [34], and it is difficult to inhibit p38 MAPK
for such a prolonged period. The aim, therefore, is to
identify surrogate markers for therapeutic responses in
acute studies that directly suggest protection against
lung destruction. Smoke-induced changes such as lung
cell apoptosis, oxidative DNA damage, and proteinase
expression would be ideal surrogate markers because
they were shown in the present study to be up-regulated
by short-term smoke exposure only in the susceptible
mouse strain, and are already associated with the patho-
genesis of human COPD [21-23]. Systemic administra-
tion of SB203580 in the present study significantly
ameliorated not only CS-induced inflammation as repre-
sented by BALF neutrophils, lung mRNA of TNF-α and
MIP2, and lung protein of KC, MIP-1α, IL-1β and IL-6
but also proteinase expression as measured by lung
MMP-12, apoptosis of alveolar septal cells as demon-
strated by ssDNA, and cleaved caspase-3 immunostain-
ing and oxidative DNA damage as measured by 8-
OHdG (Figure 3J). Discrepancy between mRNA and
protein expressions of TNF-α in response to acute CS
was observed in the present study. This discrepancy was
also noted in our previous study [24] and it is speculated
that cleaved form of TNF-α, but not total content of
TNF-α in the lung, might be important for triggering in-
flammation. Moreover, therapeutic administration of the
MAPK inhibitor is sufficient to inhibit lung inflamma-
tion caused by acute CS exposure (Figure 4B). Takentogether, these results might provide a further basis for
p38 MAPK inhibition in COPD therapeutics.
It is not clear how the p38 MAPK inhibitor suppressed
smoke-induced changes leading to lung destruction.
However, recent studies revealed that the p38 MAPK
pathway regulates apoptosis, inflammation, and fibrosis,
which are potentially associated with COPD pathogen-
esis [16,35,36]; 1) inflammatory neutrophil cell migra-
tion, 2) proinflammatory cytokine and chemokine
release from inflammatory cells and airway smooth
muscle, 3) release of degradative enzymes (eg, MMPs)
and growth factors, 4) control of the production of
interferon-γ from CD4 positive andCD8 positive T cells,
and T-helper 1 differentiation of CD4 positive cells, 5)
enhancement of bronchoconstrictor effects of airway
smooth muscle associated with inflammation and oxida-
tive stress, 6) airway remodeling, 7) induction of cortico-
steroid insensitivity. Moreover, inhaled CS stimulates
epithelial cells and alveolar macrophages to release sev-
eral chemotactic factors that attract inflammatory cells
to the lungs, including neutrophils, T-helper 1 cells, type
1 cytotoxic T cells, and fibroblasts. These inflammatory
cells, together with macrophages and epithelial cells, re-
lease proteases, growth factors, and pro-inflammatory
cytokines, causing chronic lung inflammation and struc-
tural changes [37]. This inflammation causes secondary
oxidative stress. In the present study, immunohisto-
chemical data indicated that CS activated the p38 MAPK
signaling pathway in the alveolar wall cells and bronchial
epithelial cells of C57BL/6 mice. Therefore, the adminis-
tration of SB203580 might ameliorate apoptosis and pro-
teinase production via this pathway in these cells.
Further investigation is needed to clarify the mechanism.
p38 MAPK activation and oxidative DNA damage
were significantly greater in CS susceptible strain than in
CS resistant strain in the present study. Moreover, p38
MAPK inhibition ameliorated CS-induced oxidative
DNA damage in the lung, suggesting that p38 MAPK
activation induces oxidative DNA damage in the CS ex-
posure model. On the other hand, previous papers
shown that oxidative stress induced by CS activates p38
MAPK signaling pathways of the lung [38,39]. We might
explain the complex mechanisms of cigarette smoke-
induced inflammation as follows; CS-induced oxidative
stress itself primarily activates p38 MAPK in lung cells,
followed by promoting neutrophils recruitment and sec-
ondary oxidative stress. Further investigation is needed
to clarify the mechanism.
p38 MAPK is reported to regulate mucus overproduc-
tion. Although PAS positive cells were detected in the
lungs of C57BL/6 mice after 8wk smoke-exposure in
previous publication [31], unfortunately, PAS positive
cells were not found in our C57BL/6 mice after 6 months
smoke exposure. Possible reasons are that 1) we used
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C57BL/6NCrSlc supplied from Japan SLC), 2) 6 months
smoke caused squamous formation in airway epithelial
cells (data not shown).
Several p38 MAPK inhibitors have been entered in
clinical trials for chronic inflammatory diseases such as
rheumatoid arthritis, and inflammatory bowel diseases
[40,41]. MacNee et al. reported a clinical trial in COPD
patients of the orally administrated p38 MAPK inhibitor
PH-797804 showing significant improvement of lung
function and respiratory symptoms [42]. Notably,
medium dose demonstrated the highest effects in the
evaluation of the dose–response effects. Singh explained
that the bell-shaped dose response curve might be due
to another MAPK (ERK or JNK) pathway activation by
strongly blocking p38 MAPK pathway [43]. Therefore,
optimal dose setting is important for p38 MAPK inhibi-
tors. p38 MAPK inhibitors have encountered major
problems in terms of side effects and toxicity, indicating
that it might be necessary to administer these drugs
by topical application such as inhalation to reduce sys-
temic exposure, or to target downstream substrates such
as MAPK-activated protein kinase-2 (MAPKAPK-2).
MAPKAPK-2 was reported to be essential for lipopoly-
saccharide (LPS)-induced endotoxic shock [44]. Al-
though p38 MAPK-knockout mice are embryonic lethal,
MAPKAPK-2-knockout mice have a normal lifespan, in-
dicating the safety of inhibiting this substrate. Alterna-
tively, suppression of p38 MAPK at a transcriptional
level, as observed in NZW mice, might be a safe ap-
proach. NZW mice appear to avoid unnecessary inflam-
mation by maintaining total p38 at lower levels, thus
ensuring a minimal defense response. Indeed, no reports
have suggested that NZW mice are susceptible to
infection.
The present study had some limitations. First, p38
MAPK activation/inhibition was examined in only one
susceptible strain, although it was compared with a re-
sistant strain. The roles of p38 MAPK are reported to be
different not only between strains but also between cell
types and stimulation. As suggested by humans and ani-
mal models [45], the pathogenesis of COPD/emphysema
is heterogeneous, so it would be preferable to examine
the effect of p38 MAPK inhibition in multiple suscep-
tible strains. However, the fact that lung p38 MAPK is
present at higher levels in COPD patients than in
healthy subjects suggests that p38 activation is a com-
mon feature in COPD. p38 inhibition might therefore be
successful in patients with higher levels of p38 MAPK
activation. Second, the effect of p38 inhibition was ex-
amined only in acute CS exposure. There remains a
need to explore whether CS-induced emphysematous
changes could be ameliorated by the administration of
p38 MAPK inhibitors. Our study showed, however, thatSB203580 could ameliorate not only lung inflammation
but also excessive proteinase production, oxidative DNA
damage, and apoptosis, indicating the further possibility
of using p38 MAPK inhibitors as a new drug for the
treatment of COPD. Alternatively, a chronic smoke
study using mice genetically modified in the p38 MAPK
pathway might provide additional information. Third, we
investigated only whether p38 MAPK inhibition could
ameliorate the “CS-induced” development of COPD. It
remains unclear whether p38 MAPK inhibition can sup-
press the progression of COPD that persists after smok-
ing cessation. Although airway inflammation continues
after cessation and emphysema still progresses [46], fur-
ther investigation is needed to understand this.
Conclusions
CS activated p38 MAPK only in a mouse strain that was
susceptible to CS-induced emphysema, and its selective
inhibition ameliorated lung inflammation and injury in a
murine model of CS exposure. These results demon-
strate the significance of p38 MAPK activation in COPD
pathogenesis, and might establish a basis for using
MAPK pathways as a new molecular target for the treat-
ment of COPD.
Additional file
Additional file 1: Figure S1. Acute cigarette smoke model A.B.
Apoptosis in the lungs. ssDNA-positive or cleaved caspase-3-positive cells
(arrow) in the alveolar septa are shown. C. Airway mucus overproduction.
PAS positive cells were not detected in both strains. Figure S2. p38
MAPK activation. A. In a preliminary time course experiment (n = 1), the
phosphorylation of p38 MAPK in the lungs was confirmed at 0.25, 1, 3,
and 6 h after the start of CS exposure in C57BL/6 mice, but not in NZW
mice. The phosphorylation of ERK and SAPK/JNK was noted in both
strains. B. Chronic CS exposure did not affect phosphorylation of p38
MAPK in both strains (n = 3). p-p38 MAPK, phosphorylated-p38 MAPK;
t-p38 MAPK, total p38 MAPK. C.D. Both acute (C) and chronic (D) CS
exposure caused a marked increase in the number of phosphorylated
p38-positive cells (arrow) in the alveolar walls of C57BL/6 mice, but not in
NZW mice. E-H. Acute CS exposure did not affect lung mRNA expressions
of p38 MAPK (E), MAPKAPK-2 (F), MKK3 (G), and MKK6 (H) in both
strains (n = 6). I. Chronic CS exposure up-regulated p38 MAPK mRNA in
C57BL/6 mice but not in NZW mice (n = 6). *p < 0.05 compared with
corresponding non-smoke groups. †p < 0.05 compared with C57BL/6
smoke groups. Figure S3. chronic cigarette smoke model. A.B. Apoptosis in
the lungs. ssDNA-positive or cleaved caspase-3-positive cells (arrow) in
the alveolar septa are shown. C. Airway mucus overproduction. PAS
positive cells were not detected in both strains. Figure S4. acute
cigarette smoke model (therapeutic model). There was no significant
difference in the bronchoalveolar lavage cell differential (n = 6): macrophage
(A), neutrophil (B), and lymphocyte (C).
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